Fundraising FoxSixty Degree Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Cyber Fund III portfolio company that completed an initial public offering.
Herndon, US
Christopher Bradley DeMay(Executive Officer)Jaye Alison Alfers(Executive Officer)Simon Mark Davidson(Director)John Sheldon Serafini(Executive Officer, Director)inArthur Lewis Money(Director)David Farnsworth(Director)
Co-investorsAlumni VenturesCenter15 CapitalGula Tech AdventuresHemisphere Ventures LLCIceNineManhattan Venture Partners+15 more
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSanofi VenturesSofinnova PartnersVIVES PartnersApollo Health Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.